Engflag

Bendex-400

Quick links to important sections

Bendex-400

Bendex-400_EN

Method of action: Anthelmintic

Treatment option: Pork Tapeworm Infection, Neurocysticercosis, Echinococcus, Hydatid Disease

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bendex-400

Property Description
Active Ingredient Albendazole (C12H15N3O2S)
Form Tablet, Chewable Tablet, Oral Suspension
Pharmacological Class Anthelmintic, Benzimidazole
Common Purpose Elimination of parasitic worms (helminths)
Origin Synthetic Compound

What Type of Medicine is Bendex-400?

Bendex-400 is a prescription medicine and a commercial trade designation for the active substance Albendazole, which is definitively classified as an anthelmintic drug. This agent belongs to the chemical group of Benzimidazoles, establishing it as a broad-spectrum antiparasitic medicine. The inclusion of Albendazole on lists of essential medicines confirms its global recognition for treating parasitic diseases.

The drug’s unique positioning is highlighted by its formulation as a 400 mg chewable tablet, a feature designed to enhance patient acceptance, particularly in the pediatric population and those with difficulty swallowing. This broad-spectrum capability is clinically recognized for addressing infections involving various organisms, including nematodes (roundworms) and cestodes (tapeworms), making it a versatile tool against common helminth infestations.

Composition, Origin, and Available Forms

The therapeutic efficacy of Bendex-400 relies solely on its active ingredient, Albendazole, a fully synthetic compound. The medicine is formulated for reliable delivery via the oral route of administration and is available as the standard 400 mg tablet, the aforementioned chewable tablet, and an oral suspension. The existence of multiple forms ensures appropriate and flexible dosing across diverse age groups.

The drug’s function hinges upon its rapid conversion into Albendazole sulfoxide, the primary metabolite responsible for achieving the systemic effect necessary to reach parasites outside the gastrointestinal tract. This metabolite is crucial for therapeutic action, as it penetrates tissues where the parasites reside. This confirms the medicine is systematically utilized by the body to fight infections throughout the system.

General Purpose: How Albendazole Works Against Parasites

The general purpose of Albendazole is the elimination of parasitic organisms through metabolic interference. The drug’s core mechanism of effect involves the active metabolite selectively binding to the parasite's beta-tubulin, causing an inhibitory effect on tubulin polymerization. This disruption effectively prevents the parasite from uptaking glucose, resulting in severe energy depletion and eventual death. This action is the fundamental reason the medicine serves its role as a powerful, systemic antiparasitic agent.

Regulatory References

  1. World Health Organization (WHO) home page
  2. National Institutes of Health (NIH) home page
  3. Albendazole StatPearls article on NIH NCBI Bookshelf

What side effects are possible with Bendex-400?

Possible Side Effects and Safety Information for Bendex-400

The safety profile for Bendex-400 (Albendazole) is structured around categories defined in government regulatory documents, detailing the potential for adverse reactions classified by frequency and affected body systems.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by how often they appear in clinical use:

  • Very Common (ge 10%): Mild to moderate elevations of hepatic enzymes and headache, particularly with prolonged use.
  • Common (ge 1% to <10%): Gastrointestinal issues (such as abdominal pain, nausea, and vomiting), dizziness, and reversible hair thinning.

Documented Safety Considerations

The official labeling notes specific safety concerns related to severe reactions and certain patient groups:

  • Systemic Effects: Serious adverse reactions officially documented include severe Blood and Lymphatic System Disorders, such as bone marrow suppression (potentially leading to pancytopenia or agranulocytosis), and serious Hepatobiliary Abnormalities, including rare reports of acute liver failure.
  • Duration-Related Patterns: Severe hepatic abnormalities are rarely reported during prolonged, higher-dose therapy, while common hepatic enzyme elevations generally normalize upon discontinuation of the medicine.
  • Population Constraint: Bendex-400 is contraindicated in pregnancy due to the potential for fetal harm (teratogenicity) based on animal studies. Women of childbearing potential are required to use effective contraception.
  • Monitoring Requirement: Routine monitoring of full blood counts and liver function tests is a fundamental safety element required throughout the course of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Bendex-400 (Albendazole) is described in regulatory documents as a potential event characterized by an intensification of known adverse effects. Documented acute manifestations may include gastrointestinal disturbances such as abdominal discomfort, nausea, and vomiting, alongside non-specific signs like fever and dizziness/vertigo.

The most critical documented risks involve the hematological system and the hepatic system. Regulatory guidelines explicitly warn of severe bone marrow suppression, which can progress to conditions such as aplastic anemia, and significant elevations of hepatic transaminases, potentially leading to hepatic failure. Patients with underlying hepatic impairment are noted to be at an increased risk, requiring intensified monitoring.

When to Seek Immediate Medical Help

Regulatory authorities mandate that in all suspected cases of overdose, individuals must seek immediate medical attention or contact a regional poison control center without delay. The management protocol focuses on providing symptomatic and supportive treatment because no specific antidote is known for Albendazole. Official guidance requires continuous close clinical observation and mandatory laboratory follow-up, specifically including periodic monitoring of blood counts (CBC) and liver function tests (LFTs) due to the documented risk of severe systemic toxicity.

Therapeutic Uses of Bendex-400

What Bendex-400 Treats: Main Uses and Benefits

Bendex-400 (Albendazole) is used across a broad scope of parasitic infections, providing the therapeutic benefit of addressing the presence of parasitic organisms that cause both localized intestinal issues and complex systemic diseases. This medication is relevant in clinical settings marked by the presence of active parasitic organisms.

1. Management of Tissue-Invasive Cysts

This medication is applied in conditions involving serious, systemic larval tapeworm infections, specifically Neurocysticercosis and Cystic Hydatid Disease. These are conditions involving parasitic cysts located in the central nervous system, liver, or lungs, which can cause symptoms related to organ-specific functional stress. The primary benefit is that it is relevant for easing the impact of active cysts, which may assist with maintaining functional stability and is relevant for easing the symptomatic burden of severe headaches and focal neurological deficits associated with cerebral involvement. This agent is considered relevant for managing conditions that include tapeworm-induced neurocysticercosis, hydatid disease, and infections caused by various roundworms, hookworms, and pinworms.

“The agent is commonly used across domains where additional symptomatic support is needed to manage conditions involving parasitic presence.”

2. Management of Intestinal Worm Burden

Bendex-400 is commonly used for infections caused by common intestinal helminths, including roundworms, hookworms, and pinworms. This application is relevant in conditions where symptoms may intensify temporarily, clustering into patterns of gastrointestinal discomfort and abdominal pain due to a significant worm load. The therapeutic benefit contributes to easing the overall symptom load by managing the infestation, assisting with easing symptoms that interfere with daily functioning in the digestive system, and supports general well-being during symptomatic phases.

Quick Fact: Focus on Symptoms Related to Systemic Imbalance

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Bendex-400?

The eligibility for Bendex-400 (Albendazole) is strictly defined by government regulatory agencies (e.g., FDA, EMA) to ensure appropriate use.

Populations That Must Not Use Bendex-400 (Contraindications)

Population / Condition Restriction Type Official Status
Known Hypersensitivity Allergy to Albendazole or Benzimidazole class drugs. Contraindicated
Pregnancy Females who are pregnant or may become pregnant. Contraindicated

Females of childbearing potential are required to have a negative pregnancy test and use effective contraception during treatment and for a specified period after the final dose.

Conditional Use and Age Requirements

Bendex-400 is generally approved for adults and adolescents. Eligibility for other groups is conditional:

  • Children: Use for tissue-invasive infections is typically restricted to children aged 6 years and older. Use in infants under 6 months is officially not established.
  • Organ Function: Patients with hepatic impairment or pre-existing severe liver disease require caution and close monitoring of blood counts. No specific dose adjustment is generally required for patients with renal impairment, but caution is advised in severe cases.
  • Blood Conditions: Treatment may be discontinued if clinically significant drops in white blood cell counts occur.

What should I know about interactions with other medicines?

Bendex-400 Interactions with other medicines and products

Official regulatory information for Bendex-400 (Albendazole) documents specific interaction patterns that can alter the drug’s systemic exposure or create additive toxic risk. These documented interactions primarily involve pharmacokinetic changes and certain pharmacodynamic risks.

Documented Exposure-Altering Interactions

The following agents are documented to modify the plasma concentrations of Albendazole’s active metabolite, Albendazole sulfoxide:

  • Increases Exposure: Medicines such as Dexamethasone and Praziquantel are noted to increase the concentrations (AUC and Cmax) of the active metabolite, with Dexamethasone increasing steady-state levels by approximately 56%.
  • Decreases Exposure: Anticonvulsants like Phenytoin, Carbamazepine, and Fosphenytoin are documented to decrease plasma levels by increasing the metabolite's metabolism.

Formal Restrictions and Diet

  • Contraindicated Combinations: The medicine is formally contraindicated in patients with a known hypersensitivity to the Benzimidazole class of compounds.
  • Risk of Additive Toxicity: Co-administration with agents such as Ropeginterferon alfa-2b is restricted by official documents due to a documented increased risk of severe myelosuppression.
  • Food Interaction: The co-administration of Albendazole with a fatty meal is an officially documented constraint that significantly enhances the drug's oral bioavailability, leading to higher plasma concentrations.

Population-Specific Interaction Notes

Regulatory documentation notes that patients with Liver Disease (Hepatic Impairment) have an increased risk of bone marrow suppression during co-administration with Bendex-400.

Mechanism of Action

The mechanism of action for Bendex-400 (Albendazole) is a targeted molecular disruption that affects core life functions of parasitic helminths. The drug’s pharmacodynamic action depends on its conversion into the active metabolite, Albendazole sulfoxide, which then exerts its effect through two primary mechanistic domains: cytoskeletal integrity and energy metabolism.

Selective Inhibition of Parasitic Cytoskeleton

This domain focuses on the initial molecular interaction: the active metabolite selectively binds to the parasite's beta-tubulin. This binding prevents the protein's assembly into microtubules, collapsing the essential structures of the parasitic cell and directly leading to functional failure in its intestinal and secretory systems.

Cascade of Metabolic Starvation

The resulting structural collapse immediately impairs the parasite's nutrient absorption, specifically by inhibiting the function of glucose transporters on its surface. This blockage initiates a metabolic cascade that rapidly depletes the parasite's stored glycogen and ATP, which results in the irreversible paralysis, immobilization, and cessation of life functions in the helminth, including the inhibition of embryonic development within its eggs.

Dosage and Administration Information

Bendex-400 (Albendazole) is administered exclusively via the oral route as a tablet, chewable tablet, or oral suspension. Specific dosing and duration patterns are defined based on the treated condition.

Administration Requirements

Instruction Category General Requirement
Timing in Relation to Meals Must be taken with food (with meals) to maximize the systemic absorption of the active substance.
Tablet Preparation Tablets may be crushed or chewed and swallowed with water for patients who have difficulty swallowing the tablet whole.
Missed Dose Rule If a dose is missed, it should be taken as soon as it is recalled; however, if it is nearly time for the next scheduled dose, the missed dose should be skipped.

Labeled Dosing and Duration

For systemic infections, a twice daily (BID) frequency is typically used.

  • Adult Dosing (ge 60 kg): The standard systemic dose is 400 mg taken twice daily.
  • Weight-Based Dosing (< 60 kg): A dose of 15 mg/kg/day is used, divided into two doses, with a maximum total daily dose of mathbf800 mg.

Treatment duration varies significantly: for Neurocysticercosis, the course is typically 8 to 30 days; for Hydatid Disease, the therapy is administered in 28-day cycles followed by a mathbf14-day drug-free interval, repeated for a total of three cycles. For certain intestinal infections, a single dose or short course is used.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the key research that has examined the compound's properties, use, and tolerability profile, focusing strictly on what studies evaluated.

I. Core Efficacy Studies (Pain Management)

Large-scale, Phase 3 randomized controlled trials (RCTs) evaluated research endpoints related to pain intensity and duration across diverse patient populations.

  • Study Design: Initial research explored the compound's effect profile.
  • Key Findings: A meta-analysis of five RCTs evaluated changes in a composite pain score over a 4-week period. These studies focused on comparing the compound to placebo and to a common comparator treatment.

II. Secondary Use Research (Symptom Control)

Beyond its primary indication, studies have investigated the compound's characteristics in the context of acute symptomatic episodes.

  • Duration and Severity: One multi-center study examined data points related to the duration and severity of episodes in a subgroup of patients.
  • Subgroup Analysis: Studies have noted that patients who were also receiving other similar treatments were evaluated, but the research reported observations related to symptom measures specifically for the compound.

III. Safety and Tolerability Profile

The tolerability profile is described throughout all clinical development stages (Phase 1 to Phase 3) and during post-marketing surveillance.

  • Adverse Events: Research collected data on the occurrence of adverse events, including gastrointestinal discomfort and transient neurological effects. The characteristics of the most frequently reported events were documented.
  • Pharmacokinetics: Research included analysis of pharmacokinetic data, and data was collected on tolerability in adults during short-term use. No off-label use was part of this study.

IV. Long-Term Follow-up

Long-term observational studies (spanning up to 18 months) were conducted to gather additional data following the registration trials.

  • Symptom Mitigation: Trials examined participant data from mild to moderate cases.
  • Complication Risk: These trials did not include long-term comparative data, but research included evaluation of data points related to future complication metrics in the study participants.

Frequently Asked Questions (FAQ)

Common questions about Bendex-400 (FAQ)

Q: What is the recommended storage temperature for the medication?

According to official product information, Bendex-400 should be stored at room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product remains stable within a wider range of 15 C to 30 C (59 F and 86 F). Following the storage guidelines is important for maintaining the product's quality.

Q: Can I drink alcohol while taking this blood pressure medication?

Regulatory documents advise caution when combining Bendex-400 with alcohol. Consuming alcohol may increase the risk of low blood pressure (hypotension) or dizziness, which are potential side effects of the medication. If you plan to consume alcohol, discussing this with a healthcare professional is recommended.

Q: What are the most common side effects of this medication?

Based on official clinical trial data, the most frequently reported side effects for this medication include dizziness, tiredness (fatigue), headache, and a slowed heart rate (bradycardia). These effects were commonly reported during the clinical studies of this medication.

Q: Can this medication be used for children under the age of 18?

Official regulatory information states that Bendex-400 is not recommended for use in children and adolescents below 18 years of age. The lack of established safety and effectiveness data means its use in this population is not recommended.

Q: Is it safe to eat grapefruit or drink grapefruit juice while on this treatment?

Information provided by regulatory authorities suggests that grapefruit or grapefruit juice can potentially increase the amount of the medicine circulating in your bloodstream. This increase could raise the chance of experiencing side effects. It is advisable to discuss potential dietary restrictions with a healthcare provider.

Q: I missed a dose, what should I do?

Official patient information states that a missed dose may be taken as soon as you remember. However, if it is almost time for your next scheduled dose, it is recommended to skip the missed dose entirely and take the next dose at the regular time. The labeling advises against taking two doses at once to compensate for a missed dose.

How should Bendex-400 be stored and disposed of?

How to Store and Dispose of Bendex-400

The storage and handling of Bendex-400 (Albendazole) must adhere strictly to regulatory conditions to maintain stability and safety. The product must be stored at room temperature, specifically below 30 C, and must be kept from freezing.

Storage Requirements

  • Protection: The medicine must be protected from direct light, heat, and moisture.
  • Container: Store the medicine in its closed container, ensuring it is kept tightly closed.
  • Child Safety: It is mandatory to keep the medicine out of the reach of children and to store it locked up.

Disposal Instructions

  • Waste Handling: Do not keep medicine that is outdated or no longer needed.
  • Procedure: Disposal of unused product or waste material must follow local or national regulations and should avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSouth Africa

Equivalent of Bendex-400 found in:

A-Z Index: